This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 12 Q&As
Facts about WAP four-disulfide core domain protein 2.
Human | |
---|---|
Gene Name: | WFDC2 |
Uniprot: | Q14508 |
Entrez: | 10406 |
Belongs to: |
---|
No superfamily |
dJ461P17.6; EDDM4; Epididymal secretory protein E4; epididymis-specific, whey-acidic protein type, four-disulfide core; HE4; HE4MGC57529; Major epididymis-specific protein E4; Putative protease inhibitor WAP5; WAP domain containing protein HE4-V4; WAP four-disulfide core domain 2; WAP four-disulfide core domain protein 2; WAP5; WAP5epididymal protein 4; WFDC2
Mass (kDA):
12.993 kDA
Human | |
---|---|
Location: | 20q13.12 |
Sequence: | 20; NC_000020.11 (45469753..45481532) |
Secreted.
In this article, we'll examine how to use the WFDC2 marker to measure the periostin protein. The protein is an essential component of a variety of human tissues. Boster scientists are able to utilize the marker in their research and receive credits. The marker is available to scientists from all regions of the world. Its benefits extend far beyond animal research.
Recently, the WFDC2 marker was identified as a significant player within the estrogen pathway of the ovarian cancer. While the marker is effective in detecting changes in this gene, it isn't known whether it is involved in regulating the growth of tumors. It is currently being studied to determine the function it plays. In the meantime, these results suggest that this biomarker has numerous therapeutic applications. Below are a few of the possible applications for WFDC2.
Although the WFDC2 genes are present in many tissues, it is most common in the lung and trachea. It is also expressed in subsets of epithelial cells of the pulmonary system. WFDC2, SLPI and elafin are co-expressed, suggesting that WFDC2 might play an important role in the immune system that protects your respiratory tract. This is consistent with the notion that disregulation of the proteinase/antiproteinase balance may play a role in preventing or presenting with respiratory conditions.
The differentiation status of ALI-TBE cells can affect the transcription of the WFDC2 gene. The expression of the WFDC2 genes is not controlled by classical pro-inflammatory mediators. These results suggest that WFDC2 is a significant factor in the immune system and could be used as a valuable tool in the diagnosis of a variety of diseases. With all the advantages of WFDC2 gene expression it's easy to understand why it's being used in a variety of medical research studies.
WFDC2 expression is found in human tissues that are normal, apart from the male reproductive system. It is also found in subsets of pulmonary epithelial cancer cells. Therefore, the coexpression of WFDC2 with SLPI and the WFDC2 marker suggests that these proteins play a role in the defense of the host against the respiratory tract. Further, it has been suggested that disregulation of proteinase/antiproteinase balance may contribute to the development of respiratory conditions.
SLPI and WFDC2 genes reside on chromosomes 20q12-13.1. They are part of a set of genes called WAP. These genes are closely related and are also co-expressed by WFDC2. WFDC2 is involved in the development of numerous cancers, such as those triggered by sex hormones. It is believed to be associated with an increased risk of developing cancer of the ovary.
SLPI and WFDC2 are both members of the Whey Acidic Protein family. It is a glycoprotein with 25 kDa that has two WAP domains. Although it is expressed in the salivary gland, lung, and various other tissues, it isn't well-characterized. The WFDC2 gene has also been associated with an increased risk of colon cancer among patients with inflammatory bowel diseases.
The WFDC2 marker is utilized in many areas of oncology. It could also be used in lung cancer research. It has been suggested that serum WFDC2 may be a sensitive marker for the disease. Continue reading to discover more about this fascinating marker. Here are a few examples of its applications:
WFDC2 can be detected in human tissues that are normal, in addition to the male reproductive system. It is also present in a subset pulmonary epithelial-derived tumor cells. This protein is involved in the protection of the respiratory tract. Its co-expression with SLPI, WFDC2, and elafin suggests this. Its role in the development of respiratory diseases is thought to be related to the disregulation of proteinase/antiproteinase balance.
WFDC2 is involved in oncology research and is also expressed by salivary glands. WFDC2 is found in some cells of the respiratory tract which includes nasal passages and the oral cavity. It is also present in the ductular cell and major salivary glands. The protein is not present in the lungs that are peripherally located.
A new study has identified WFDC2 as a promising immunotherapy that fights cancer. WFDC2 activation can be found in a variety of cancer cells and shows a different regulation of pro-inflammatory stimuli. However, this gene is not activated by LPS or TNFa, two of the most commonly used inflammatory mediators. It is also not induced by bacteria's products.
Scientists can determine Human WFDC2 using the Human HE4 ELISA Kit. Each kit includes 96 wells that can be used to analyze 96 samples as well as strips that can be removed. This technique allows researchers to determine the amount of WFDC2 in different samples and is applicable to all scientists, regardless of whether they are in the lab or abroad. Furthermore it can be used to evaluate the expression of multiple proteins in the same sample.
The WFDC2 marker is a potential cancer biomarker, and could assist in monitoring the disease's progress. Multiple studies have evaluated its expression, including immunohistochemistry as well as molecular classification array experiments. It has been discovered that it is not regulated in certain types of cancers of the ovary. However its presence in other kinds of cancers does not prove this. Certain researchers have found a link between WFDC2 and subtypes of adenocarcinomas and lung cancer.
The technique is usually built around color changes or a chromogenic reader. The latest techniques, such as ELISA-like immunostaining make use of fluorescent, electrochemical or quantitative PCR. Each reporter has its own benefits such as multiplexing, higher sensitivity, and non-enzymatic reporters. Because these new assays are not enzyme-linked, they are typically combined with ELISAs.
This method is typically used to determine the presence of target proteins within a tissue section. It involves selecting the target regions and applying streptavidin-conjugated HRP and a peroxide substrate. The optical density of the proteins were compared with an a standard curve reference to which was obtained by parallel staining of slides coated with target protein. The resulting optical densities were used to estimate target protein content.
ELISA is a highly sensitive and precise method of measuring proteins. It was first introduced in 1971 and has been a vital instrument in clinical labs since then. ELISA can be used to screen individual samples, or in a fully automated, high-throughput method. It is one of the few methods that can simultaneously measure a wide range of target proteins simultaneously. There are some flaws. It needs to be a pool of samples.
Ovarian cancer is a disease of the reproductive organs. There are three types of cancers of the ovary: epithelial, sex cord/stromal tumors and germ cell tumors. These tumors are classified in accordance with their cellular nature and histopathological features. Each subtype is subdivided into multiple subtypes. These cancers of the ovary can present a wide variety of pathomorphological features. A large portion is cystic, and has solid elements.
RNA-Seq is a powerful tool for detecting cancer of the ovary. It is a highly effective tool for assessing the expression of genes, identifying alternatively expressed transcripts, and detecting abnormal genes. It is particularly useful in ovarian cancer detection as it is able to detect the presence of tumors that are infiltrating earlier. It also comes with a wide variety of benefits, including the identification of abnormal molecular pathways. The information gathered can to improve treatments and provide more information to cancer patients.
MRI has been widely used as a problem-solving tool for patients who suspect ovarian cancer. Its outstanding functional properties and soft contrast of tissue make it perfect for differentiation and identification from solid adnexal masses. It is not meant to replace CT for the purpose of staging ovarian cancer. A combination of both methods is required to make the most effective decisions for each patient. If an MRI is carried out on a patient who is suspected of having cancer of the ovarian lining the results are vital in the decision-making process.
The WFDC2 marker is a glycosylated 25 kDa protein made up of two Whey Acidic Protein (WAP) domains and one peptide. It is located on chromosome 20,q12-13.1 and is in close proximity to other members of the WAP family. Although it is not fully identified as to its biological function however, it has been proven to have antibacterial and antiinflammatory properties.
The results of the meta-analysis suggest that the serum HE4 can be a useful biomarker for the diagnosis of lung cancer. However, there are some limitations to this study, for example, its low sensitivity and limited specificity. To confirm the results it will require extensive research. The results are encouraging and warrant further research. Jia-xi, Jian-qi Nian and Yongpeng He supported this study.
WFDC2 is located in the lungs as well as other organ tissues during lung cancer. This protein, also known by HE4, is secreted into the blood and can be detected in the serum. This marker can help in determining the extent of the cancer and the treatment response. The WFDC2 gene is present in a wide variety of cancer tissues, including ovarian and fallopian tube cancer.
PMID: 1686187 by Kirchhoff C., et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.
PMID: 11965550 by Bingle L., et al. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms.
*More publications can be found for each product on its corresponding product page